8 March 2021
Now in its fourth year, the Global Health 50/50 2021 Report, Gender equality: Flying blind in a time of crisis reviews the 201 most influential organisations active in global health, including the Medicines Patent Pool, to assess how gender equality is being advanced within organisations and health programmes, taking an in-depth look at gender in health-related COVID-19 responses. Again this year, MPP is listed among 33 high scorer on gender equality and part of the top 45.
Despite a calamitous 2020, the report finds notable areas of progress and hope. The new data and research show that organisational commitment to gender equality is surging, and that organisations are becoming more transparent about their policies on shaping diverse, inclusive and equitable working environments for people.
However all is not rosy, the report’s latest data suggests that rhetoric is often used as a substitute for action and that programmatic activity to prevent and address the health impacts of COVID-19 largely ignores the role of gender. Yet gender influences everything from who gets tested for COVID-19 to risk of severe disease and death. The result is gender-blind pandemic responses that are less effective than they should be, with grave consequences for the health of billions of people around the world.
Read the report
Access MPP’s final scoring
Array ( [0] => Array ( [acf_fc_layout] => post_grid [show_latest_posts] => [post_grid_layout] => rectangular [background_colour] => bg-pale-yellow [posts_per_row] => 2 [posts_to_display_in_grid] => Array ( [0] => WP_Post Object ( [ID] => 1806 [post_author] => 1 [post_date] => 2020-03-09 11:56:51 [post_date_gmt] => 2020-03-09 11:56:51 [post_content] => Gender plays a key role in determining health and well-being across the lifecourse. The Global Health 50/50’s report Power, Privilege and Priorities published today provides the only birds-eye view of gender and equality in the global health system. The report reviews the gender-related policies and practices of 200 organisations, including the Medicines Patent Pool which has been listed as a high scorer on gender equality. The report presents data highlighting two major inequalities that impede progress towards the health-related United Nations’ Sustainable Development Goals (SDGs): inequality of opportunity in career pathways inside global health organisations, and inequality of benefits from the global health system. The report notes some progress towards gender equality, for instance, the number of organisations with public policies to advance gender equality in the workplace increased by 25% in two years and the proportion of women board chairs jumped from 20% to 26%. Progress is still needed regarding gender balance in senior leadership positions, moving past power asymmetries which see high-income countries continuing to hold disproportionate power in leadership and in setting health agendas, and an end to systematic neglect of certain health conditions,. Read the report Access MPP’s final scoring [post_title] => MPP listed as high scorer in 2020 Global Health 50/50’s report Power, Privilege and Priorities [post_excerpt] => Gender plays a key role in determining health and well-being across the lifecourse. The Global Health 50/50’s report Power, Privilege and Priorities published today provides the only birds-eye view of gender and equality in the global health system. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-listed-as-high-scorer-in-2020-global-health-50-50s-report-power-privilege-and-priorities [to_ping] => [pinged] => [post_modified] => 2020-04-15 12:03:36 [post_modified_gmt] => 2020-04-15 11:03:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://medicinespatentpool.org/?post_type=news-publications&p=1806 [menu_order] => 229 [post_type] => news-publications [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 1710 [post_author] => 1 [post_date] => 2019-03-08 10:01:19 [post_date_gmt] => 2019-03-08 10:01:19 [post_content] => For the first time in 2019, the Medicines Patent Pool took part in the Global Health 50/50 2019 Report, Equality Works, released on the occasion of International Women's Day. The report takes an in-depth look at the gender-related policies and practices of 198 organisations active in global health, with a special focus on gender in the workplace, looking at policies around sexual harassment, parental leave and reports of gender pay gaps. Access the report [post_title] => 2019 Global Health 50/50 Report [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => 2019-global-health-50-50-report [to_ping] => [pinged] => [post_modified] => 2020-04-15 10:04:06 [post_modified_gmt] => 2020-04-15 09:04:06 [post_content_filtered] => [post_parent] => 0 [guid] => https://medicinespatentpool.org/?post_type=news-publications&p=1710 [menu_order] => 349 [post_type] => news-publications [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [number_of_posts_to_show] => -1 [post_type] => news-publications [disease_styles] => [news_publication_type] => [people_type] => [company_type] => [story_type] => [include_filters] => [show_images] => 1 [show_events_from_date] => all ) )
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.